MedPath

GeneQuantum Healthcare (Suzhou) Co., Ltd.

GeneQuantum Healthcare (Suzhou) Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (100.0%)

A Study of GQ1010 in Subjects With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Malignant Solid Tumors
Interventions
Drug: Dose Expansion1
Drug: Dose Expansion3
Drug: Dose Escalation
Drug: phase II
Drug: Dose Expansion2
First Posted Date
2024-06-18
Last Posted Date
2025-02-10
Lead Sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Target Recruit Count
260
Registration Number
NCT06464055
Locations
🇨🇳

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China

🇨🇳

Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China

🇨🇳

Tianjin medical university cancer institute & hospital, Tianjin, China

and more 2 locations

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Phase 1
Recruiting
Conditions
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
Interventions
First Posted Date
2023-12-04
Last Posted Date
2023-12-04
Lead Sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Target Recruit Count
150
Registration Number
NCT06154343
Locations
🇨🇳

Chinese PLA general hospital, Beijing, Beijing, China

🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

and more 16 locations

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Phase 1
Recruiting
Conditions
HER2-positive Biliary Tract Cancer
HER2-Positive Salivary Gland Carcinomas
HER2-positive Breast Cancer
HER2-Positive Advanced Solid Tumor
Interventions
First Posted Date
2020-06-29
Last Posted Date
2023-12-05
Lead Sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Target Recruit Count
96
Registration Number
NCT04450732
Locations
🇺🇸

M.D. Anderson Cancer Center, Houston, Texas, United States

🇦🇺

Scientia Clinical Research Limited, Randwick, New South Wales, Australia

🇦🇺

Cabrini Institute in Melbourne, Australia, Melbourne, Victoria, Australia

and more 21 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.